Through HealthXL, Roche Diagnostics is to collaborate with innovative Connected Health companies globally
At TechTour’s Healthtech Summit in Switzerland, HealthXL – global market for health innovation –announced that Roche Diagnostics joins the HealthXL network to collaborate with industry leaders and innovative connected health companies globally.
Roche Diagnostics joins a network of 17 HealthXL partners including leading global healthcare brands such as Bupa, Cleveland Clinic, Becton Dickinson, IBM, ICON, ResMed, Janssen Healthcare Innovation, Linde Healthcare, Novartis, Partners HealthCare, Silicon Valley Bank, EY, SoftServe, Hermitage Medical Clinic, SoftLayer, Apollo Hospitals, Children’s Hospital Los Angeles.
“Through HealthXL, we will further expand our activities in the Connected Health and Chronic Disease Management domain globally by exploring the opportunities to collaborate with other HealthXL partners, as well as with innovative connected health companies”, said Jochen Hurlebaus, Head of Central R&D Services – Innovation and IP Management at Roche Diagnostics.
The announcement came during a talk by Martin Kelly, CEO, HealthXL on “Trends in Digital Health Investments and Ecosystems” at TechTour’s Healthtech Summit yesterday in Lausanne, Switzerland. “Roche Diagnostics is the global leader for diagnostics and we are delighted to have them on board. Bringing a clinical diagnostics partner will help the partners in our network to bridge bench side diagnostics to the wider ecosystem of connected care”, said Martin Kelly, CEO and Founder of HealthXL.
HealthXL and its clients are constantly exploring similar opportunities in healthcare to work with high growth companies, increasing the speed at which existing digital health technologies can begin to have a meaningful impact on health outcomes.
